Joint Formulary & PAD

Baricitinib - Rheumatoid arthritis

You are here : Home > Formulary Search > Baricitinib - Rheumatoid arthritis

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Red
Formulations :
  • Tablets
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
Guidelines
ICB
NICE
SPC
Restrictions / Comments :

Documentation

NICE Technology Appraisal
NICE TA466 - Baricitinib for moderate to severe rheumatoid arthritis
Evidence Review
Baricitinib for moderate to severe rheumatoid arthritis - Briefing paper - November 2017
Webpage
MHRA risk warning - JAK inhibitors - Apr 23

PAD Profile

ChemicalSubstance :
Baricitinib
Indication :
Rheumatoid arthritis
Group Name :
Keywords :
RA, Immunomodulator, Protein Kinase Inhibitor, JAK inhibitor, Janus Kinase, NICE TA, JAKI, RA, Biologic, NICE, immunosuppressant, DMARD, bDmard, Disease modulating, Rheumatology, cytokine modulator,
Brand Names Include :
Olumiant
Important Information :
Severe disease only
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Rheumatoid arthritis
Supporting Documents :
3

Committee Recommendations (1)

01 Nov 17 - Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

The PCN recommends baricitinib as a treatment option for the treatment of severe Rheumatoid Arthritis in line with NICE TA466 Prescribing will be by hospital specialists only, in line with NICE TA466 using Blueteq initiation and continuation forms. Baricitinib will be considered RED on the traffic light system

Other Indications

Below are listed other indications that Baricitinib is used to treat.

Other Drugs

Below are listed other drugs that are used to treat Rheumatoid arthritis.